MITOCONIX BIO
Mitoconix Bio is pioneering a disease-modifying strategy of improving mitochondrial functions for treating neurodegenerative diseases. Mitochondria generates ATP, the energy source for all cellular activities. Mitochondria are also involved in other essential cellular functions, including calcium sequestration, amino acid and lipid metabolism, keeping balanced redox potential and orchestrating programmed cell death. In neurons in particular, mitochondria are very dynamic organelles that constan... tly undergo fission (division) and fusion. This process, called mitochondrial dynamics, is critical in maintaining healthy and functional mitochondria under both normal conditions and in response to stress and in ensuring having viable mitochondria along the axons and in the synaptic boutons. A defect in either fusion or fission limits mitochondrial motility, decreases energy production, increases oxidative stress and activates pro-apoptotic signaling thereby promoting cell dysfunction and death. Mitoconixโ lead drug is a first-in-class inhibitor of pathological mitochondrial fragmentation and dysfunction with demonstrated in vivo efficacy in animal models of Huntingtonโs (HD) and Parkinsonโs diseases (PD) and beneficial activity in patient-derived cells of HD, sporadic and genetic PD, and sporadic and genetic Alzheimerโs disease (AD).
MITOCONIX BIO
Industry:
Biotechnology Health Care Life Science
Founded:
2016-01-01
Address:
Jerusalem, Yerushalayim, Israel
Country:
Israel
Website Url:
http://www.mitoconix.com
Total Employee:
1+
Status:
Closed
Total Funding:
20 M USD
Technology used in webpage:
Domain Not Resolving Shutterstock
Current Employees Featured
Founder
Investors List
RM Global Partners
RM Global Partners investment in Series A - Mitoconix Bio
Arix Bioscience
Arix Bioscience investment in Series A - Mitoconix Bio
Dementia Discovery Fund
Dementia Discovery Fund investment in Series A - Mitoconix Bio
OrbiMed
OrbiMed investment in Series A - Mitoconix Bio
Remiges Ventures
Remiges Ventures investment in Series A - Mitoconix Bio